Repligen Corporation (NASDAQ:RGEN) - Stock analysts at Jefferies Group increased their Q3 2017 EPS estimates for Repligen Corporation in a research report issued on Friday. Jefferies Group analyst B. Couillard now anticipates that the biotechnology company will post earnings of $0.15 per share for the quarter, up from their prior estimate of $0.13. Jefferies Group currently has a “Hold” rating and a $40.00 price target on the stock. Jefferies Group also issued estimates for Repligen Corporation’s Q4 2017 earnings at $0.12 EPS, FY2017 earnings at $0.61 EPS, Q2 2018 earnings at $0.19 EPS, Q3 2018 earnings at $0.18 EPS, Q4 2018 earnings at $0.18 EPS, FY2018 earnings at $0.72 EPS and FY2019 earnings at $0.88 EPS.
Repligen Corporation (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.05. The company had revenue of $32.40 million for the quarter, compared to analyst estimates of $31.72 million. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. Repligen Corporation’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter last year, the business earned $0.16 EPS.
WARNING: This piece was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://stocknewstimes.com/2017/08/19/repligen-corporation-to-post-q3-2017-earnings-of-0-15-per-share-jefferies-group-forecasts-rgen-updated.html.
RGEN has been the topic of several other research reports. Janney Montgomery Scott upped their price objective on shares of Repligen Corporation from $42.00 to $47.00 in a research note on Friday, June 23rd. First Analysis reissued an “equal weight” rating and issued a $40.00 target price on shares of Repligen Corporation in a research report on Friday, April 21st. Zacks Investment Research raised shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $43.00 target price for the company in a research report on Thursday, May 11th. BidaskClub downgraded shares of Repligen Corporation from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 14th. Finally, William Blair began coverage on shares of Repligen Corporation in a research report on Friday, July 21st. They issued an “outperform” rating for the company. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $41.20.
Repligen Corporation (RGEN) opened at 42.78 on Monday. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of 112.88 and a beta of 1.30. The company’s 50 day moving average is $41.52 and its 200 day moving average is $36.21. Repligen Corporation has a 12-month low of $26.16 and a 12-month high of $46.81.
Several institutional investors have recently made changes to their positions in the stock. Norges Bank acquired a new position in shares of Repligen Corporation during the fourth quarter worth about $8,527,000. Teachers Advisors LLC boosted its position in shares of Repligen Corporation by 11.4% in the fourth quarter. Teachers Advisors LLC now owns 56,695 shares of the biotechnology company’s stock worth $1,747,000 after buying an additional 5,819 shares in the last quarter. Macquarie Group Ltd. boosted its position in shares of Repligen Corporation by 481.1% in the fourth quarter. Macquarie Group Ltd. now owns 319,668 shares of the biotechnology company’s stock worth $9,852,000 after buying an additional 264,659 shares in the last quarter. Bank of Montreal Can boosted its position in shares of Repligen Corporation by 26.1% in the first quarter. Bank of Montreal Can now owns 37,036 shares of the biotechnology company’s stock worth $1,304,000 after buying an additional 7,675 shares in the last quarter. Finally, Louisiana State Employees Retirement System boosted its position in shares of Repligen Corporation by 1.5% in the first quarter. Louisiana State Employees Retirement System now owns 13,800 shares of the biotechnology company’s stock worth $486,000 after buying an additional 200 shares in the last quarter. Institutional investors own 99.02% of the company’s stock.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
